Php297 - Changes in Ultra-Orphan Drug Assessments in Poland

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1191
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Psy60 - Orphan Versus Ultra-Orphan Drugs Prices in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Economic Evaluation and Cost-Effectiveness Threshold in Practice of Decision-Making on Orphan Drug Reimbursement in Poland

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Orphan and Ultra-Orphan Technologies: European and Australian Payer Perceptions

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Orphan Drug Pricing in France: Influence of Main Factors

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Orphan Drug Approvals in Europe: Historical Review and Trends

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Php109 - Cost of Unlicenced and Orphan Medicines in Turkey, Kazakhstan and Poland

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Orphan Drug Development in China ‒ Turning Challenges Into Opportunities

Intractable and Rare Diseases Research
Medicine
2016English

Time to Revisit the Orphan Drug Law

European Journal of Clinical Pharmacology
MedicinePharmacology
2011English

Pmu32 - Orphan Drug Prices in Europe: Impact of External Reference Pricing

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy